Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies

Why It Matters

The long‑term efficacy data strengthen UX111’s case for regulatory approval and could establish the first disease‑modifying gene therapy for a neurodegenerative lysosomal disorder, opening a sizable market and setting a precedent for CNS‑targeted AAV treatments.

Key Takeaways

• UX111 shows sustained cognitive gains up to 8.5 years.
• Highest dose (3×10¹³ vg/kg) given to 27 patients.
• Early treatment yields 23.3‑point Bailey‑III improvement.
• Older children retain communication and ambulation abilities.
• FDA resubmission targets decision by Q3 2026.

Pulse Analysis

Sanfilippo syndrome type A, or MPS IIIA, is a rare lysosomal storage disorder caused by mutations that block heparan sulfate breakdown, leading to progressive neurodegeneration. Ultragenyx’s investigational AAV‑based gene therapy UX111 delivers a functional copy of the N‑acetyl‑α‑glucosaminidase gene directly to the central nervous system, aiming to halt substrate accumulation. The approach follows a growing trend of in‑vivo gene therapies that use a single intravenous infusion to achieve durable expression in neurons. By targeting the disease’s root cause, UX111 promises a disease‑modifying solution rather than symptomatic care.

The latest long‑term readout, presented at WORLDSymposium 2026, combined data from the Transpher A study (28 patients) and a smaller cohort, totaling 33 dosed participants, with 27 receiving the top dose of 3 × 10¹³ vg/kg. Children treated before age two showed a 23.3‑point gain on the Bailey‑III scale, a clinically meaningful jump in communication and motor function. Older patients maintained verbal, non‑verbal, ambulation and self‑feeding skills beyond the natural‑history median loss age. Biomarker analysis revealed a rapid, sustained drop in cerebrospinal fluid heparan sulfate within one month, confirming target engagement.

Despite the encouraging efficacy signals, the FDA denied UX111’s original biologics license in July 2025, citing deficiencies in chemistry, manufacturing, and controls rather than product safety. Ultragenyx addressed those gaps and resubmitted the application on Jan. 30, 2026, anticipating a six‑month review and a decision by the third quarter. Approval would give the company its first gene‑therapy product for a neurodegenerative indication and could unlock a multi‑hundred‑million‑dollar market, while also setting a regulatory precedent for future CNS‑targeted AAV therapies.